One of the major problems faced by men on taxotere (chemotherapy) is anemia. Anemia is characterized as a low red blood cell count. It is often the cause of significant fatigue, another major complaint from men on chemotherapy. Aranesp® and Procrit® are both synthetic versions of the naturally occurring hormone, erythropoietin, that stimulates red blood [...]
Is there any reason to continue hormone therapy (ADT) while I have become castrate resistant and I’m starting chemotherapy? This is a common question that is asked by many of us. The real underlying question we are asking is: I feel so terrible now and I am getting ready to add chemotherapy with all of [...]
UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]
What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]
A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]